Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 3/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17271376 | 1.00 | KDM4E (0.36) | KDM4EGAAKMT2ASMARCA2SMARCA4 | |
| SCHEMBL9902438 | 0.93 | KDM4E (0.41) | KDM4EGAAKMT2ASMARCA2SMARCA4 | |
| SCHEMBL9902354 | 0.89 | KDM4E (0.34) | KDM4EGAAKMT2AJAK2JAK1 | |
| SCHEMBL9902819 | 0.89 | KDM4E (0.34) | KDM4EGAAKMT2A | |
| SCHEMBL16994502 | 0.89 | KDM4E (0.34) | KDM4EGAAKMT2AJAK2JAK1 | |
| SCHEMBL9902157 | 0.86 | KDM4E (0.44) | KDM4EGAAKMT2A | |
| SCHEMBL16994495 | 0.86 | KDM4E (0.44) | KDM4EGAAKMT2A | |
| SCHEMBL17271384 | 0.86 | KDM4E (0.44) | KDM4EGAAKMT2A | |
| SCHEMBL9902321 | 0.86 | KDM4E (0.34) | KDM4EGAAKMT2A | |
| SCHEMBL9902498 | 0.85 | MEN1 (0.37) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522903-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2016-12-20 | — | — | US | claimed |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | claimed |
| US-9522903-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOX3 | KDM4E 1377/4885GAA 1484/4885KMT2A 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.